ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bioverativ and Bicycle Therapeutics will work together to develop treatments for hemophilia and sickle cell disease. Under the pact, Bicycle scores $10 million up front and $4 million in research funding from Bioverativ, a blood disorder company that was spun off of Biogen earlier this year. Bicycle will develop chemically constrained peptides, which combine the target specificity of an antibody with the tissue penetration of a small molecule, through lead optimization. Bioverativ will handle preclinical and clinical studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X